Table 1.
Demographic and clinical characteristics of the MM patients
| Variables | Newly diagnosed MM
|
||
|---|---|---|---|
| All patients (N = 156) | CD45+ cohort (N= 43) | CD45− cohort (N=113) | |
|
| |||
| Age * | 67 (39 – 95) | 66 (48 – 95) | 68 (39–90) |
|
| |||
| Male (No, %) | 94 (60%) | 29 (67%) | 65 (58%) |
|
| |||
| PCLI %* | 0.8 (0 – 8.6) | 1 (0 – 8.6) | 0.8 (0 – 6) |
|
| |||
| Bone marrow PC%* | 45 (5 – 100) | 50 (5 – 95) | 45 (5 – 100) |
|
| |||
| LDH * | 159 (3 – 878) | 160 (75 – 878) | 159 (3 – 656) |
|
| |||
| Beta-2-microglobulin * | 5.0 (1.7 – 27.2) | 5.0 (2.4 – 27.2) | 3.8 (1.4 – 19.3) |
|
| |||
| Creatinine * | 1 (0.4 – 7.6) | 1.1 (0.6 – 4.9) | 1.0 (0.4 – 7.6) |
|
| |||
| Albumin * | 3.5 (2.3 – 4.5) | 3.5 (2.4 – 4.5) | 3.5 (2.3 – 4.3) |
|
| |||
| High risk FISH (152 pts only) (No, %) | 43 (28%) | 7 (17%) | 36 (32%) |
| Deletion 17p/Monosomy 17 | 28 | 4 | 24 |
| t(4;14) | 14 | 2 | 12 |
| t(14;16) | 7 | 1 | 6 |
| t(14;20) | 1 | 0 | 1 |
|
| |||
| ISS stage at diagnosis (Available on 147 pts only) (No, %) | |||
| • Stage 1 | 43 (29%) | 12 (29%) | 31 (29%) |
| • Stage 2 | 59 (40%) | 13 (32%) | 46 (43%) |
| • Stage 3 | 45 (31%) | 16 (39%) | 29 (28%) |
|
| |||
| Induction therapy (No, %) | |||
| Novel agents | 153 (98%) | 42 (98%) | 111 (98%) |
| • Thalidomide | 10 (6%) | 1 (2%) | 9 (8%) |
| • Lenalidomide | 104 (67%) | 28 (65%) | 76 (67%) |
| • Bortezomib | 56 (35%) | 20 (47%) | 36 (32%) |
|
| |||
| Upfront post-induction ASCT (No, %) | 50 (32%) | 13 (30%) | 37 (33%) |
*
Median (Range)